Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pucotenlimab + Lenvatinib + Irinotecan for Relapsed/Refractory Hepatoblastoma
NCT07188311Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2025
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pucotenlimab in hepatoblastoma, sponsored by Sun Yat-sen University. Started Apr 2025; status: recruiting.
02
Drugs
pucotenlimab
03
Conditions
hepatoblastoma
Beyond the preview
Go deeper on NCT07188311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07188311.